Xiaoheng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaoheng Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jinbo Cheng
College of Life & Environmental Science, Center on Translational Neuroscience, Minzu University of China, Beijing, China
1 shared publication - Lin Hou
Department of Biochemistry and Molecular Biology of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, P.R. China
1 shared publication - Yuan Dong
Neuropsychiatry Research Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China
1 shared publication
Latest Publications
- Open Access
- 28 January 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 558
Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?
Alzheimer’s disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.
- 28 January 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 558
Open AccessDrug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?
Alzheimer’s disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.